A better understanding of mechanisms regulating PD-L1 expression in the tumor microenvironment (TME) may help us clarify the clinical utility of PD-L1 expression or even immunotherapy-based treatments in CRC. This evidence concerns the gene CD274 and colorectal carcinoma.